Comparative Pharmacology
Head-to-head clinical analysis: FORTESTA versus TESTODERM TTS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTESTA versus TESTODERM TTS.
FORTESTA vs TESTODERM TTS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Testosterone is an androgen receptor agonist. It binds to and activates androgen receptors, leading to changes in gene expression that promote the development and maintenance of male secondary sexual characteristics, anabolic effects, and spermatogenesis.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
Apply 4 mg (one 4 mg/24 hr system) or 6 mg (one 6 mg/24 hr system) transdermally once daily, applied to clean, dry, intact skin on the back, abdomen, thighs, or upper arms. Rotate application sites with an interval of at least 7 days.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
The terminal elimination half-life of testosterone administered transdermally is approximately 1.5–2 hours. This short half-life requires daily application of the patch to maintain therapeutic levels.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Testosterone is excreted primarily in the urine as glucuronide and sulfate conjugates (approximately 90%), with about 6% excreted in feces via bile. Less than 1% is excreted unchanged.
Category C
Category C
Androgen
Androgen